Neos Therapeutics (Neos Therapeutics) Retained Earnings : $-352.25 Mil (As of Sep. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Neos Therapeutics's retained earnings for the quarter that ended in Sep. 2020 was $-352.25 Mil.

Neos Therapeutics's quarterly retained earnings declined from Mar. 2020 ($-341.84 Mil) to Jun. 2020 ($-347.34 Mil) and declined from Jun. 2020 ($-347.34 Mil) to Sep. 2020 ($-352.25 Mil).

Neos Therapeutics's annual retained earnings declined from Dec. 2017 ($-265.31 Mil) to Dec. 2018 ($-316.98 Mil) and declined from Dec. 2018 ($-316.98 Mil) to Dec. 2019 ($-333.89 Mil).

Neos Therapeutics Retained Earnings Historical Data

The historical data trend for Neos Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics Retained Earnings Chart

Neos Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Retained Earnings

Get a 7-Day Free Trial

-116.79

-200.12

-265.31

-316.98

-333.89

Neos Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Retained Earnings	Get a 7-Day Free Trial															-330.40	-333.89	-341.84	-347.34	-352.25

Neos Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Neos Therapeutics (NAS:NEOS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Neos Therapeutics (Neos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

2940 N. Highway 360, Grand Prairie, TX, USA, 75050

Website

http://www.neostx.com

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.

Executives

Alan L Heller	director	BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille	director
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin	director, officer: Chief Executive Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli	officer: SVP & General Counsel	700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell	officer: Chief Commercial Officer	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg	officer: Chief Executive Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking	officer: VP, Regulatory Affairs	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens	officer: Chief Tech/Operations Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355